This is a standard annual shareholder meeting with no material financial impact. Shareholders should vote on the proposals, but no significant changes to company strategy or operations are expected.
NMRA drugs
NMRA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 20 $2.19entry
- T+1 · 7mo ago +5.94%α +6.59% · $2.32
- T+5 · 7mo ago +1.37%α +0.46% · $2.22
- T+20 · 6mo ago −19.18%α −23.38% · $1.77
- T+60 · 4mo ago −25.57%α −32.35% · $1.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Neumora Therapeutics, Inc. is holding its 2026 annual meeting of stockholders. The proxy statement outlines proposals for the election of three directors, ratification of the independent auditor, and advisory votes on executive compensation. This is a routine corporate governance filing.
Key Financial Metrics
Key Facts
- Neumora Therapeutics, Inc. is holding its 2026 annual meeting of stockholders.
- Proposals include the election of three Class III directors: Paul Berns, Matthew Fust, and David Piacquad.
- Shareholders are asked to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm.
- Advisory votes on the compensation of named executive officers and the frequency of future advisory votes are also on the agenda.
Financial Impact
Routine corporate governance matters; no direct financial impact.
Risk Factors
- Failure to ratify the auditor could lead to delays in financial reporting, but this is highly unlikely.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-161519 |
| Document: 0001193125-26-161519-index-headers.html | 0001193125-26-161519 |
| Document: 0001193125-26-161519-index.html | 0001193125-26-161519 |
| Document: 0001193125-26-161519.txt | 0001193125-26-161519 |
Track record
14 reports on NMRA
3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
- Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
- Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
- Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
- Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
- Aug 14, 202613w ago 8-K Neutral 4/10 No price data
- Aug 14, 202613w ago Press Release Neutral 4/10 Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
- Jul 27, 202616w ago 8-K Bullish 5/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
- Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers